Description:
The purpose of this study is to evaluate the objective response, safety, and tolerability of
pembrolizumab in Japanese participants who have refractory primary mediastinal large B-cell
lymphoma.
Title
- Brief Title: A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33)
- Official Title: A Phase 1 Clinical Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (KEYNOTE-A33)
Clinical Trial IDs
- ORG STUDY ID:
3475-A33
- SECONDARY ID:
MK-3475-A33
- SECONDARY ID:
KEYNOTE-A33
- SECONDARY ID:
205262
- NCT ID:
NCT04317066
Conditions
Interventions
Drug | Synonyms | Arms |
---|
Pembrolizumab | KEYTRUDA®, MK-3475 | Pembrolizumab in Participants with rrPMBCL |
Purpose
The purpose of this study is to evaluate the objective response, safety, and tolerability of
pembrolizumab in Japanese participants who have refractory primary mediastinal large B-cell
lymphoma.
Trial Arms
Name | Type | Description | Interventions |
---|
Pembrolizumab in Participants with rrPMBCL | Experimental | Participants with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) receive pembrolizumab 200 mg by intravenous (IV) infusion every 3 weeks (Q3W) for up to 24 months. | |
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of Primary mediastinal B-cell lymphoma (PMBCL)
- Relapsed or refractory PMBCL and:
- Relapsed after auto-stem cell transplantation (SCT) or have failed to achieve a
CR or PR within 60 days of auto-SCT; or
- For participants who are ineligible for auto-SCT, has received at least ≥ 2 lines
of prior therapy and have failed to respond to or relapsed after their last line
of treatment. For participants who received consolidative local radiotherapy
after systemic therapy, local radiotherapy will not be considered as a separate
line of treatment.
- Previously exposed to rituximab as part of prior lines of treatment.
- Radiographically measurable disease
- Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
Performance Scale.
- Life expectancy ≥3 months.
- Adequate organ function.
- Male participants of childbearing potential must agree to use an adequate method of
contraception, starting with the first dose of study drug through 120 days after the
last dose of study drug, OR must be abstinent from heterosexual intercourse as their
preferred and usual lifestyle (abstinent on a long term and persistent basis) and
agree to remain abstinent.
- Female participants of childbearing potential must be willing to use an adequate
method of contraception for the course of the study through 120 days after the last
dose of study drug, OR must be abstinent from heterosexual intercourse as their
preferred and usual lifestyle (abstinent on a long term and persistent basis) and
agree to remain abstinent.
Exclusion Criteria:
- Received prior therapy with an anti-PD-1 (programmed cell death protein 1), anti-PD-L1
(programmed death-ligand 1), or anti-PD-L2 (programmed cell death 1 ligand 2), or with
an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.,
CTLA-4 [cytotoxic T-lymphocyte-associated protein 4], OX 40, or CD137 [cluster of
differentiation 137])
- Received chimeric antigen receptor (CAR) T-cell therapy.
- Prior monoclonal antibody or radiation therapy within 4 weeks prior to the first dose
of study intervention; OR received prior chemotherapy or targeted small molecule
therapy within 2 weeks prior to the first dose of study intervention; OR has not
recovered from adverse events due to a previously administered agent above.
Participants with ≤ Grade 2 neuropathy are an exception to this criterion and may
qualify for the study.
- Major surgery within 3 weeks prior to first dose of study intervention.
- Received a live vaccine within 30 days prior to the first dose of study drug.
- Currently participating in or has participated in a study of an investigational agent
or has used an investigational device within 4 weeks prior to the first dose of study
intervention. Participants in the follow-up phase of an investigational study may
participate as long as it has been 4 weeks after the last dose of the previous
investigational agent.
- Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any
other form of immunosuppressive therapy within 7 days prior the first dose of study
drug.
- Known additional malignancy that is progressing or has required active treatment
within the past 3 years. Exceptions include basal cell carcinoma of the skin, squamous
cell carcinoma of the skin, or carcinoma in situ, that have undergone potentially
curative therapy.
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- Severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
- Active autoimmune disease that has required systemic treatment in past 2 years
- History of (non-infectious) pneumonitis that required steroids, or current
pneumonitis.
- Active infection requiring systemic therapy.
- History of human immunodeficiency virus (HIV) or Hepatitis B.
- Active Hepatitis C virus infection.
- Known psychiatric or substance abuse disorder that would interfere with the
participant's ability to cooperate with the requirements of the study.
- Pregnant or breastfeeding, or expecting to conceive or father children within the
projected duration of the study, starting with the screening visit through 120 days
after the last dose of study intervention.
- Allogeneic hematopoietic stem cell/solid organ transplantation within the last 5
years.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Objective Response Rate (ORR) as Assessed by Independent Central Review |
Time Frame: | Up to approximately 5 years |
Safety Issue: | |
Description: | ORR is defined as the percentage of participants who have a Complete Response (CR) or Partial Response (PR). The percentage of participants who experience a CR or PR as assessed by blinded independent central review will be presented. |
Secondary Outcome Measures
Measure: | Objective Response Rate (ORR) as Assessed by Investigator |
Time Frame: | Up to approximately 5 years |
Safety Issue: | |
Description: | ORR is defined as the percentage of participants who have a Complete Response (CR) or Partial Response (PR). The percentage of participants who experience a CR or PR as assessed by investigator review will be presented. |
Measure: | Disease Control Rate (DCR) as Assessed by Independent Central Review |
Time Frame: | Up to approximately 5 years |
Safety Issue: | |
Description: | DCR is defined as the percentage of participants who have a Complete Response (CR), a Partial Response (PR), or stable disease (SD). The percentage of participants who experience a CR, a PR, or SD as assessed by blinded independent central review will be presented. |
Measure: | Disease Control Rate (DCR) as Assessed by Investigator |
Time Frame: | Up to approximately 5 years |
Safety Issue: | |
Description: | DCR is defined as the percentage of participants who have a Complete Response (CR), a Partial Response (PR), or stable disease (SD). The percentage of participants who experience a CR, a PR, or SD as assessed by investigator review will be presented. |
Details
Phase: | Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Merck Sharp & Dohme Corp. |
Trial Keywords
- Programmed Cell Death-1 (PD1, PD-1)
- Programmed Death-Ligand 1 (PDL1, PD-L1)
Last Updated
November 6, 2020